Fred Aslan - 15 May 2025 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Role
President and CEO, Director
Signature
/s/ Neha Krishnamohan, Attorney-in-Fact
Issuer symbol
ARTV
Transactions as of
15 May 2025
Net transactions value
-$91,403
Form type
4
Filing time
18 Aug 2025, 20:15:13 UTC
Previous filing
07 Mar 2025
Next filing
17 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Aslan Fred President and CEO, Director C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO /s/ Neha Krishnamohan, Attorney-in-Fact 18 Aug 2025 0001909362

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARTV Common Stock Tax liability $9,525 -4,472 -1.1% $2.13 412,193 15 May 2025 Direct F1
transaction ARTV Common Stock Sale $69,579 -25,500 -6.2% $2.73 386,693 15 Aug 2025 Direct F2, F3
transaction ARTV Common Stock Tax liability $12,298 -4,472 -1.2% $2.75 382,221 15 Aug 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
F2 Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 23, 2024, to satisfy income tax obligations associated with the vesting of restricted stock unit awards.
F3 The weighted average sale price for the transaction reported was $2.7286, and the range of prices were between $2.60 and $2.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.